CN102743770B - A kind of targeting molecule image probe and living body molecule imaging method - Google Patents
A kind of targeting molecule image probe and living body molecule imaging method Download PDFInfo
- Publication number
- CN102743770B CN102743770B CN201210200690.6A CN201210200690A CN102743770B CN 102743770 B CN102743770 B CN 102743770B CN 201210200690 A CN201210200690 A CN 201210200690A CN 102743770 B CN102743770 B CN 102743770B
- Authority
- CN
- China
- Prior art keywords
- targeting
- probe
- component
- imaging
- affine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000523 sample Substances 0.000 title claims abstract description 92
- 238000003384 imaging method Methods 0.000 title claims abstract description 63
- 230000008685 targeting Effects 0.000 title claims abstract description 63
- 108010069241 Connexin 43 Proteins 0.000 claims abstract description 143
- 102000001045 Connexin 43 Human genes 0.000 claims abstract description 140
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 claims abstract description 37
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 25
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
- 206010003119 arrhythmia Diseases 0.000 claims abstract description 8
- 230000006793 arrhythmia Effects 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 239000007850 fluorescent dye Substances 0.000 claims description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 12
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 11
- 101100294331 Drosophila melanogaster nod gene Proteins 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims description 8
- 230000002159 abnormal effect Effects 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 230000003287 optical effect Effects 0.000 claims description 7
- SYFGLWDDLZQFNI-UHFFFAOYSA-N 2-[4-(carboxymethyl)-1,4,8,11-tetrazabicyclo[6.6.2]hexadecan-11-yl]acetic acid Chemical compound C1CN(CC(O)=O)CCCN2CCN(CC(=O)O)CCCN1CC2 SYFGLWDDLZQFNI-UHFFFAOYSA-N 0.000 claims description 6
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical group OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 6
- -1 NODAGA Chemical compound 0.000 claims description 6
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 2
- 208000027205 Congenital disease Diseases 0.000 claims 1
- 208000037919 acquired disease Diseases 0.000 claims 1
- 230000008859 change Effects 0.000 abstract description 12
- 238000009826 distribution Methods 0.000 abstract description 10
- 238000012360 testing method Methods 0.000 abstract description 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 40
- 239000003068 molecular probe Substances 0.000 description 27
- 239000000126 substance Substances 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 20
- 210000002216 heart Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 210000003462 vein Anatomy 0.000 description 12
- 239000002738 chelating agent Substances 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 238000002600 positron emission tomography Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000002096 quantum dot Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 239000002105 nanoparticle Substances 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 230000009870 specific binding Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000001588 bifunctional effect Effects 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 230000005291 magnetic effect Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 210000004165 myocardium Anatomy 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000000747 cardiac effect Effects 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 238000000799 fluorescence microscopy Methods 0.000 description 6
- 108010075130 AAP 10 Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004413 cardiac myocyte Anatomy 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000003387 muscular Effects 0.000 description 5
- 230000005298 paramagnetic effect Effects 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 102000010970 Connexin Human genes 0.000 description 4
- 108050001175 Connexin Proteins 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000009739 binding Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003976 gap junction Anatomy 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- GFJRASPBQLDRRY-TWTQBQJDSA-N rotigaptide Chemical compound NC(=O)CNC(=O)[C@@H](C)NC(=O)CNC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@@H]1N(C(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(C)=O)CCC1 GFJRASPBQLDRRY-TWTQBQJDSA-N 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 3
- 241000581650 Ivesia Species 0.000 description 3
- 238000012879 PET imaging Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003288 anthiarrhythmic effect Effects 0.000 description 3
- 239000003416 antiarrhythmic agent Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000004700 cellular uptake Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003147 molecular marker Substances 0.000 description 3
- 239000002086 nanomaterial Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- NVOVSXGZALWAFS-UHFFFAOYSA-N 3,6,10,13,16,19-hexazabicyclo[6.6.6]icosane Chemical compound C1NCCNCC2CNCCNCC1CNCCNC2 NVOVSXGZALWAFS-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 101710176384 Peptide 1 Proteins 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000002318 cardia Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- CBFCDTFDPHXCNY-UHFFFAOYSA-N icosane Chemical compound CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000015250 liver sausages Nutrition 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000001455 metallic ions Chemical class 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000012634 optical imaging Methods 0.000 description 2
- 230000005408 paramagnetism Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Substances [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- PWHWEEINSXYFAE-LMANFOLPSA-N (4-nitrophenyl) 2-(18F)fluoranylpropanoate Chemical compound [N+](=O)([O-])C1=CC=C(C=C1)OC(C(C)[18F])=O PWHWEEINSXYFAE-LMANFOLPSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- NSTREUWFTAOOKS-UHFFFAOYSA-N 2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1F NSTREUWFTAOOKS-UHFFFAOYSA-N 0.000 description 1
- OOLRAQKFMNOZBV-UHFFFAOYSA-N 8-n-[(4-aminophenyl)methyl]-3,6,10,13,16,19-hexazabicyclo[6.6.6]icosane-1,8-diamine Chemical compound C1=CC(N)=CC=C1CNC1(CNCCNC2)CNCCNCC2(N)CNCCNC1 OOLRAQKFMNOZBV-UHFFFAOYSA-N 0.000 description 1
- KLZUFWVZNOTSEM-UHFFFAOYSA-K Aluminum fluoride Inorganic materials F[Al](F)F KLZUFWVZNOTSEM-UHFFFAOYSA-K 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000008058 Reciprocating Tachycardia Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108010070783 alanyltyrosine Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- MDKCFLQDBWCQCV-UHFFFAOYSA-N benzyl isothiocyanate Chemical compound S=C=NCC1=CC=CC=C1 MDKCFLQDBWCQCV-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910001429 cobalt ion Inorganic materials 0.000 description 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- OSTIHFXUTPZJQL-UHFFFAOYSA-N fluoro benzoate Chemical compound FOC(=O)C1=CC=CC=C1 OSTIHFXUTPZJQL-UHFFFAOYSA-N 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 238000003333 near-infrared imaging Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002907 paramagnetic material Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 108010054669 rotigaptide Proteins 0.000 description 1
- 229950005893 rotigaptide Drugs 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000026676 system process Effects 0.000 description 1
- 229940056501 technetium 99m Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Acoustics & Sound (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to medical technical field, more particularly to a kind of living body molecule imaging method and targeting molecule image probe.Living body molecule imaging method of the present invention reflects disease of cardiovascular system in the form of images by introducing the targeting molecule image probe for being available for iconography equipment to detect(Especially arrhythmia cordis)With the inserted by connexin 43 of the disease such as tumour(Cx43)Biochemical change feature, testing result is accurate, can intuitively show Cx43 distribution and quantity, may be directly applied to human body.Cx43 targeting molecules image probe disclosed by the invention, targets affine component by signal component, Cx43 and the part of connector three is constituted, with good Pharmacokinetic Characteristics and biodistribution feature.
Description
Technical field
The present invention relates to medical technical field, more particularly to a kind of Cx43 targeting molecules image probe and living body molecule into
Image space method.
Background technology
Gap Junction Remodelling(gap junction remodeling)It is to participate in arrhythmia cordis, tumour, atherosclerosis
One of common pathologic basis occur etc. disease, developed, and inserted by connexin 43(Connexin43, Cx43)It is then composition seam
The fundamental structural unit of gap connection, is the primary structure basis of gap connection between composition cardiac muscle cell.Cx43 is that molecular weight is
A kind of 43Kd connection albumen, its main function is to mediate the Direct Communication between flanking cell.In heart, its main function is
Form iuntercellular quickly electricity impulsion, it is ensured that heart entirety electrical activity synchronism and harmony, maintain the electrical activity of cardiac muscle cell
And the synchronism of Mechanical Contraction and diastolic function.Therefore, Cx43 is sent out in terms of quantity, distribution, function and phosphorylation state
It is raw to change(That is Gap Junction Remodelling)When will necessarily cause electrical coupling obstacle between cardiac muscle cell.It is mainly shown as iuntercellular electrical activity
Synchronism, coordinate sexually revise, conducting speed slow down and it is anisotropic change etc..A variety of acquired angiocarpy of adult
Disease, such as myocardial ischemia, arrhythmia cordis, heart failure, hypertension, atherosclerosis occur in that different degrees of Cx43 seams
Gap connection reconstruct.Cx43 Gap Junction Remodellings are various arrhythmia cordis, the important feature that especially reciprocal tachycardia is produced
Basis, is also the main reason of various heart disease deaths and sudden death.
Meanwhile, Cx43 participates in various kinds of cell life cycle from the links for growing into death, direct mediate cell growth
Transmission of the adjustment signal between flanking cell, regulating cell growth, differentiation and apoptosis.Cx43 exception will result directly in cell
Adjusting and controlling growth is abnormal, and contact inhibition, terminal differentiation and apoptosis capacity disappear, and shows as extension or immortality cell life
Cycle, so as to cause tumour.
Therefore, Cx43 is used as antiarrhythmic therapy and the common molecular target spot of antineoplaston, it has also become domestic unfaithful intention
Vascular diseases and the new study hotspot in tumor research field.A variety of study in vitro are also developed accordingly, are used for
Cx43 quantity and function(Including phosphorylation state)Analysis.These research methods include:Using PCR or RT-PCR in mRNA water
Flat detection Cx43 expression;Semidefinite quantity research is carried out to Cx43 albumen using Western Blot;It is glimmering by immuning tissue
Light staining technique, observation Cx43 subcellsular level positioning and Gap Junction Remodelling etc.;By introducing the different phosphorylation positions of Cx43
The specific antibody of point, utilizes Matrix Assisted Laser Desorption/MALDI-MS, immobilized metal affinity chromatography, liquid phase tandem mass spectrum point
Analyse the phosphorylation state of Cx43 different phosphorylation sites;Tested using fluorescent dye intercellular trafficking, by microinjection side
Small molecule fluorescent dyestuff is incorporated into cytoplasm by method, and with reference to fluorescence microscopy, the thin of Cx43 mediations is evaluated in cellular level
Intercellular Direct Communication function etc..But, these external detection methods are relied primarily on to substantial amounts of, cellular level or in vitro tissue
The analysis of experimental result.
Though external detection method can determine whether, analyze the Cx43 expressions and functional status of cell or tissue, from technology
Analyzed in aspect, all there is certain limitation:
1. need to obtain sample by cell culture, biopsy or postmortem, it is impossible to directly apply to human body;
2. Vitro Experimental Results may not be inconsistent with the truth under condition of living organism:Experiment in vitro is by experiment condition, experiment
Equipment, experimental method influence it is larger, in the processing procedure of sample, some important compositions may be lost, error is larger,
So that experimental result is not inconsistent with the truth under condition of living organism;
3. experiment in vitro is unfavorable for dynamic studies:Experiment in vitro needs to put to death experimental animal to obtain at different time points
Tissue or repeatedly biopsy extraction, can only observe a certain stage of disease, it is impossible to realize that really dynamic is ground in same animal body
Study carefully, be difficult to obtain accurate conclusion in the disease overall process of such complicated, progress;
4. complex operation, much time wealth, randomness is very big.Therefore, Cx43 live body visual research may be to solve this
A little problems are there is provided a kind of new thinking, and the appearance of molecular imaging technology makes possibility.
Molecular imaging refers to that under condition of living organism image application method is to the cell and molecular water in human or animal's body
Flat biological process is imaged, qualitative and quantitative study a subject.It is used using application molecular probe as distinguishing feature
A variety of imaging means, are imaged to internal particular target point.Imaging means include:Radionuclide imaging(radionuclide
imaging), magnetic resonance imaging(Magnetic resonance imaging, MRI), magnetic resonance spectrum imaging(MR
Spectroscopy, MRS), optical imagery(Optical imaging, OI), ultrasonic imaging(Ultrasound imaging,
US)And multi-pattern Fusion imaging(integration of multi-mode imaging)Deng.It is raw by these imaging techniques
The life some specific physiology of internal system or pathologic process, such as gene expression, the interphase interaction of protein, signal transduction,
The metabolism of cell and Cellular tracking etc. can be changed into intuitively image and display.
The Cx43 visualization schemes of the progress such as V Baklaushev, have been synthesized with E2 sections outside Cx43 albuminous cells of specificity
Antibody is targets affine component, with radio isotope125I and fluorescent dye Alexa660 is the probe of signal component, utilizes γ
Ray counter and fluorescence microscope carry out the abnormal expression situation of Cx43 in detection glioma, but still without breaking away from external inspection
The limitation of checking method:
①125I is not a kind of nucleic of suitable animal scanning, can only be detected using gamma radiation counter, and is checked
As a result it is not directly perceived enough.So the research is in intravenous injection probe125After I-MAbE2Cx43, animal is put to death, tissue is obtained, using γ
Ray counter has carried out radioassay;
2. Alexa660 is not the fluorescent dye suitable for living imaging yet, is only used for immuning tissue's staining analysis,
Therefore the research puts to death animal after intravenous injection probe Alexa660-MAbE2Cx43, obtains tissue, frozen section is made,
Tissue is analyzed using fluorescence microscope;
3. using MAbE2Cx43 antibody as affine component, antibody is expensive, and may cause immunogenic response
So as to trigger side effect.Importantly, because antibody molecule amount is larger, non-specific adsorption can be higher, after being injected into vivo
It is difficult to obtain preferable Pharmacokinetic Characteristics and biodistribution feature, causes testing result inaccurate, application is not square
Just.
The method for needing In vivo detection and quantitative Cx43 badly at present.
The content of the invention
Present invention mainly solves technical problem be exactly Cx43 In vivo detection and quantitative problem.It is imaged by living body molecule
Technology carried out In vivo detection to Cx43 and quantitative, and Cx43 expression quantity, distribution, function and disease development can be determined in live body
During Cx43 dynamic change situation, specify Cx43 targeted therapies intervention Best Times, dosage, and to " rebuild Cx43 " control
The curative effect for the treatment of carries out accurate objective appraisal, so as to realize that the prognosis of the diseases such as Rapid exhumation arrhythmia cordis and malignant tumour is commented
Estimate, Cx43 targeted therapy curative effect monitorings.
On the one hand, the present invention provides a kind of method of living body molecule imaging, and methods described includes:
Cx43 targeting molecule probes are provided, the targeting molecule probe by signal component, target affine component and
The part of connector three constitute, the signal group be divided into be available for iconography equipment detect part, the affine component of targeting be with
The part of Cx43 specific bindings, the connector connects signal component and the affine component of targeting;
Implement optical imagery, positron emission to patient position to be measured with described Cx43 targeting molecules probe to break
Layer imaging, single photon emission tomographic imaging, magnetic resonance imaging, photoacoustic imaging, ultrasonic imaging or other live body iconographies are fused into
As technology preferred PET/CT, PET/MRI.
Preferably, the affine component of targeting and Cx43 carboxyl terminal are specifically bound.It is highly preferred that the targeting
Affine component is selected from:
Ith, Cx43SP1, Gly-Ala-Pro-Gly-4Hyp-Pro-Tyr
IIth, Cx43SP2, Gly-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly
IIIth, Cx43SP3, its structural formula is as follows:
IVth, Cx43SP4, including 5 kinds have RXP-X structures analog, it is specific as follows:
RXP-A, its amino acid sequence is as shown in SEQ ID No.1;
RXP-B, its amino acid sequence is as shown in SEQ ID No.2;
RXP-C, its amino acid sequence is as shown in SEQ ID No.3;
RXP-D, its amino acid sequence is as shown in SEQ ID No.4;
RXP-E, its amino acid sequence is as shown in SEQ ID No.5.
Preferably, the signal group is selected from radio isotope, fluorescent dye, quantum dot, paramagnetism material, magnetic
Property nano-particle, superparamagnetic material, ultrasonic microbubble, the one or more of optoacoustic nano particle.
Preferably, the connector be selected from DTPA, DOTA, DOTAGA, NOTA, NODAGA, TETA, CB-TE2A, Sar,
The chelating agents such as NODA or other chemical methodes that directly can be joined directly together signal component and the affine component of Cx43 targetings.
On the other hand, the present invention provides a kind of targeting molecule probe, by signal component, targets affine component and will letter
Number component and the part of connector three composition that affine component is connected is targetted, the signal group, which is divided into, is available for iconography equipment to examine
The part of survey, the affine component of targeting is the part specifically bound with Cx43, and the connector is by signal component and targeting
Affine component is connected.
Preferably, the affine component of targeting of the targeting molecule probe and Cx43 carboxyl terminal are specifically bound.
It is highly preferred that the affine component of targeting is selected from:
Ith, Cx43SP1, Gly-Ala-Pro-Gly-4Hyp-Pro-Tyr
IIth, Cx43SP2, Gly-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly
IIIth, Cx43SP3, its structure is as follows:
IVth, Cx43SP4, including 5 kinds of analogs with RXP-X structures, sequence is as follows:
RXP-X | Sequence |
RXP-A | DVPGRDPGYIKGGGSAHARVPFF SHSLNRNRKP SLYQ |
RXP-B | EIQPRSPLMFSGGGSAHARVPFFSHSAKEARWPRAHR |
RXP-C | GIAAREPNSHDGGGSAHARVPFFSHSRDLWRKPAKSL |
RXP-D | WEEPRRPFTMSGGGSAETHARVPFYSHSPMRHRLPGVHL |
RXP-E | SDDLRSPQLHNGGGSAVPFYSHSHMVRRKPRNPR |
Preferably, the signal group is selected from radio isotope, fluorescent dye, quantum dot, paramagnetism material, magnetic
Property nano-particle, superparamagnetic material, ultrasonic microbubble, the one or more of optoacoustic nano particle.
Preferably, the connector be selected from DTPA, DOTA, DOTAGA, NOTA, NODAGA, TETA, CB-TE2A, Sar,
The chelating agents such as NODA, or be directly connected to signal component and the affine components of Cx43 using other direct chemical reactions.
Molecular probe(molecular probe):Being can be with a certain specific biological molecules(Such as protein, DNA, RNA)
Or eucaryotic cell structure targeting specific combination and be available in vivo or(With)The labeled compound molecule of external iconography spike,
These labeled compound molecules can in live body or(With)Reflect in vitro its target biomolecule amount and(Or)Function.Can be simple
It is interpreted as molecular imaging diagnostics classes medicine.
Molecular imaging probe must possess following 2 key characters:Pair 1. there is height with the closely related target molecule of disease
Spend affinity and targeting specific;2. it is available for iconography equipment in vitro to carry out spike.Probe is mainly used in right in vivo
Bioprocess is imaged, quantitative and measuring study.Basic structure is generally divided into three parts:Signal component(signaling
component), affine component(affinity component)And connector(linker).Signal component refers to that shadow can be produced
As learning signal and the contrast agent that can be detected by high-precision imaging technique or label part(Such as radionuclide, fluorescein, suitable
Magnetic atom and ultrasonic microbubble etc.);Affine component is targeted molecular, is the part with imaging target spot specific binding(Such as part
Or antibody etc.).Directly signal component and affine component can be connected by radio chemistry or biomolecule click chemistry technology
Pick up and, can also pass through linker, i.e. introducing crosslinked reagent or derivatization reagent(crosslinking or derivatizing
reagents)The two is connected.
The present invention provides a kind of molecular targeted specific probes of Cx43, such probe by radio isotope, fluorescent dye,
The Imaging Methods such as quantum dot, nano-particle, magnetic material, ultrasonic microbubble, photoacoustic imaging material and multi-modal imaging are marked
Cx43 targeting specific Binding peptides are formed.Such probe is introduced, using positron emission tomography(PET), single photon hair
Penetrate tomography(SPECT), the image such as optical imagery, ultrasonic imaging, magnetic resonance imaging, photoacoustic imaging and multi-modal imaging learns to do
Section can be detected in vivo under normal physiological and pathologic condition, the Cx43 of area-of-interest quantity, distribution and function, and its
The variation characteristic of the different phase developed in disease.
Have confirmed that the probe in vivo has good stability through research, Cx43 targeted moleculars imaging specificity is high, accurately
Property it is high, the contrast of image is good, it is adaptable to disease of cardiovascular system(Especially arrhythmia cordis), tumour diagnosis, Cx43 targeting
Curative effect monitoring is treated, Best Times, the dosage of targeted therapy intervention is specified, and to " the curative effect progress for rebuilding Cx43 " treatments is accurate
Objective appraisal.Meanwhile, the also basic research for tumour and disease of cardiovascular system provides effective method, for research Cx43
The correlation between generation, Characteristics of Development with disease provides new means.
The present invention also provides a kind of image forming composition, includes above-mentioned targeting molecule probe.
The present invention also provides the targeting molecule probe in the reagent for preparing diagnosis Cx43 abnormal expression relevant diseases
Purposes.
Preferably, the Cx43 abnormal expressions relevant disease is using Cx43 expression or dysfunction as the disease of characterization of molecules
Disease, mainly includes arrhythmia cordis or tumour.
The present invention sets up noninvasive, intuitively Cx43 living body molecules imaging method, and synthesis is available for the spy that iconography equipment is detected
Pin, intuitively shows Cx43 distribution and quantity, its function of preliminary assessment, and the technology, which has, to be set up safe, noninvasive, live body, moves
State, feature that is directly perceived, accurate, may be directly applied to human body.
The class Cx43 targeting imaging diagnosis class medicines that the present invention is developed(Molecular probe), moved with good medicine generation
Mechanical characteristics and biodistribution feature, testing result are more accurate, using more facilitating, in the form of images the reflection heart directly perceived
Restrain the biochemical characteristics of the diseases such as not normal and tumour.
The targeting specific probe of the present invention has the following advantages that:
1) has Cx43 targeting specifics, it is ensured that the accuracy of Cx43 molecular imagings targeting detection
Non-specific probe used in general iconography and Nuclear medicine is unable to the life in specific recognition and combination
Thing molecule, therefore the information that disease molecules change downstream can only be provided(Dissection, pathology and physiology change), or disease is whole
The change of volume morphing and function information, such as CBF, the change of blood perfusion.If thinking accurately to detect in disease progression
Key point thing molecule, then require probe can in specific recognition and combination molecular marker there is provided disease molecular level
Information, deepens the understanding to disease organism process.In addition, using targeting specific probe, probe and other can be efficiently reduced
The non-specific binding of non-imaged target spot, more contributes to that imaging target spot is carried out accurately to quantify.
2) .Cx43 live body visualization, it is ensured that safe, the noninvasive and intuitive of Cx43 molecular imagings detection
Realize the live body visualization of key molecule mark in disease progression, it is desirable to which probe has transmitting iconography letter
Number, the performance for being available for noninvasive iconography equipment to detect in vitro intuitively shows the distribution of molecular marker by image
Situation.Because the characteristics of imageological examination has safe, noninvasive, directly perceived.
3) high-affinity of molecular probes and target spot Cx43
Cx43 In vivo detections are realized, the premise for obtaining preferable molecular imaging image is height of the molecular probe in imaging target spot
Concentration is assembled, that is, requires that probe reaches behind target area early stage just and targeted integration, the time of dissociation is relatively later, it is ensured that in several blood
After liquid cycle period, probe reaches preferable coherent condition in target spot.
4) molecular probes detect Cx43 hypersensitivity
In the situation of change for early detecting molecular marker of disease early stage, or Results, probe is usually required that
Very small amount of biomarker is can detect, i.e., with high susceptibility.In addition, preferable molecule different from medicine
Probe must assure that its biological impact produced or pharmacotoxicological effect are as far as possible low, it is therefore desirable to which the sensitiveness of probe is sufficiently high,
Only need to a small amount of probe and be achieved with preferable image, the quantity for introducing intracorporeal probe is reduced as far as possible, reduction probe triggers
Pharmacotoxicological effect.
5) high-contrast of .Cx43 living body molecules imaging
The signal intensity of the image request lesion region of high-contrast is sufficiently high, i.e. target/background ratio and signal/noise ratio
Value is very high.This requires probe to have preferable biodistribution feature, i.e. probe big in the dense poly- amount in target area, residence time
It is long, and uptake ratio is low in normal structure organ, removing speed is fast.
6) the live body stability of molecular probes
Although the introduction volume of molecular probe seldom may maintain the stability and integrality of molecular probe in vivo
A problem is still, because there are many enzymes in blood plasma or in target tissue, probe can be degraded.Picture quality and quantitatively grind
The accuracy studied carefully depends on the stability of probe in vivo.
7) immunogenicity and toxicity of molecular probes are low
Applied to human body molecular probe must safely, without immunogenicity and toxicity.The pharmacotoxicological effect of generation is tried one's best
It is low.
8) production process of molecular probes is simple and easy to do, and cost is low
The preparation process of molecular probe is convenient and easy, with low cost, helps to be widely applied in clinic.If produced
Journey is complicated, and cost height will certainly then influence the clinical conversion of molecular probe.
Brief description of the drawings
Fig. 1 is the structural representation of Cx43 targeted molecular image probes;
Fig. 2 is the fluorescent microscopy images of probe in vitro with HeLa-Cx43 cell binding experiments:
a:After Cy5.5-Cx43SP and HeLa-Cx43 cells are incubated altogether, the substantial amounts of probe of HeLa-Cx43 cellular uptakes
Cy5.5-Cx43SP(Green);
b:After Cy5.5-Cx43SP is incubated altogether with HeLa cells, Cy5.5-Cx43SP is not by control group HeLa cellular uptakes;
c:Introduce excessive un-marked Cx43SP to block in advance, then Cy5.5-Cx43SP and HeLa-Cx43 cells are total to
After incubation, HeLa-Cx43 cellular uptakes Cy5.5-Cx43SP amount is significantly reduced, and is not almost absorbed;
d:Introduce excessive un-marked Cx43SP to block, after Cy5.5-Cx43SP is incubated altogether with HeLa cells, HeLa is thin
Born of the same parents do not absorb Cy5.5-Cx43SP still.Confirm that probe has good targeting specific.
Fig. 3 is tissue freezing section's fluorescent microscopy images using muscle as control:
a:Shown under 1h after tail vein injection Cy5.5-Cx43SP, muscle frozen section fluorescence microscope, Cy5.5-
Cx43SP is in musculature without aggregation;
b:Muscle frozen section bright field pictures, show musculature morphology;
c:Muscle frozen section and fluorescence microscope figure below fusion picture.
Fig. 4 be Active MnO2 probe after, cardiac muscular tissue's frozen section fluorescent microscopy images:
a:Picture, Cy5.5- under 1h after tail vein injection Cy5.5-Cx43SP, myocardium frozen section fluorescence microscope
Cx43SP largely assembles in cardiac muscular tissue;
b:1h after tail vein injection Cy5.5-Cx43SP, myocardium frozen section bright field pictures show cardiac muscular tissue
Form;
c:1h after tail vein injection Cy5.5-Cx43SP, myocardium frozen section and fluorescence microscope figure below fusion picture is shown
Cy5.5-Cx43SP largely assembles in cardiac muscular tissue, and is distributed mainly on position where the connection of gap between cardiac muscle cell.
Fig. 5 is64Cu-NODA-Cx43SP1 is combined and blocking experiment with Hela-Cx43 cells
Fig. 6 is in vitro Main Tissues organ near-infrared fluorescence imaging:After mouse tail vein injection probe Cy5.5-Cx43SP
1h, probe is significantly built up in heart, stomach, liver, gall-bladder and enteron aisle, most of to be drained through liver sausage road.
Fig. 7 is64The PET imagings of Cu-NOTA-Cx43SP1 different time points in normal rat, display probe is poly- in heart
Collection is obvious.64The microcurie of Cu-NOTA-Cx43SP1 injection volumes about 200.
Fig. 8 is64Cu-NOTA-Cx43SP1 PET of 1 hour in normal mouse are imaged, and display probe assembles bright in heart
It is aobvious.64The microcurie of Cu-NOTA-Cx43SP1 injection volumes about 50.
Fig. 9:Intravital mouse tumour near infrared imaging is tested:1h after mouse tail vein injection probe Cy5.5-Cx43SP1,
The HeLa-Cx43 tumor locus for being overexpressed Cx43 is largely assembled, and in right side control group HeLa tumor locus without dense poly-.
Figure 10:Internal mouse tumor PET imaging experiments:Mouse tail vein injection probe641h after Cu-NODA-Cx43SP1,
Probe is largely assembled in the HeLa-Cx43 tumor locus for being overexpressed Cx43(Left side).
Embodiment
The invention discloses a kind of Cx43 targeting molecules image probe and living body molecule imaging method, people in the art
Member can use for reference present disclosure, be suitably modified technological parameter realization.In particular, all similar replacements and change
Apparent to those skilled in the art, they are considered as being included in the present invention.The method of the present invention and application
Be described by preferred embodiment, related personnel substantially can not depart from present invention, in spirit and scope it is right
Method described herein and application are modified or suitably change is with combining, to realize and apply the technology of the present invention.
In order that those skilled in the art more fully understands technical scheme, with reference to specific embodiment pair
The present invention is described in further detail.
Embodiment 1:Cx43 targets affine component -- Cx43 targeting binding peptides(Cx43SP)
4 class polypeptide below(Cx43 targeting binding peptides)Any kind can be tied with Cx43 carboxyl terminal specificity
Close, therefore can be used to synthesize Cx43 targeted molecular probes.
1), Cx43SP1 structure:
Gly-Ala-Pro-Gly-4Hyp-Pro-Tyr, also known as:AAP10, molecular formula:C26H37N7O8, molecular weight:
575.6, its structure is as follows:
Cx43SP1 is the most important affine component of targeting in molecular probe of the present invention, be a kind can be specific in vivo
Recognize Cx43, and the polypeptide of 6 amino acid composition in combination.Cx43SP1 is Aonuma S in 1980 etc. in the atrium of ox
A series of anti-arrhythmia polypeptides by acting on Cx43 and working extracted in tissue, therefore be once named as
antiarrhythmic peptide10(AAP10).But it is due to AAP10 structural instabilities in blood plasma, fails to have further
Clinical practice.Invention person has carried out chemical modification to AAP10 structures, has synthesized the spy for Cx43 living imagings
Pin, and demonstrate the probe there is preferable live body stability.Because in the present invention, the chemical constitution is not re-used as the anti-rhythm of the heart
Arrhythmic agents, but as the affine component of targeting of Cx43 targeted molecular image probes, therefore it is named as Cx43 specific bindings
Peptide 1 (Cx43 Specific Peptide 1).Cx43SP1 horseshoe-shaped structure domain can be with Cx43 carboxyl terminal acceptor knot
Structure domain is specifically bound.
2), Cx43SP2 structure:
Gly-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly, its structure is as follows:
Cx43SP2 is Cx43SP1 analog, and the part L-type amino acid in Cx43SP is instead of with D type amino acid, from
And stability is added, have been introduced into clinical experimental stage currently as antiarrhythmic drug.Cx43SP2 trade name:
Rotigaptide, also known as:CHEMBL450656, GAP-486, ZP123.Molecular formula:C28H39N7O9, molecular weight:617.65076.
3)Cx43SP3 structure:
Cx43SP3 is Cx43SP2 functional analogue, also known as GAP 134, and molecular weight is 291.3, the following institute of its structure
Show:
4)Cx43SP4 is 5 kinds of amino acid sequences comprising RXP-E characteristic structurals, as shown in table 1:
The Cx43SP4 of table 1 amino acid sequence
RXP-X | Sequence |
RXP-A | DVPGRDPGYIKGGGSAHARVPFFSHSLNRNRKPSLYQ |
RXP-B | EIQPRSPLMFSGGGSAHARVPFFSHSAKEARWPRAHR |
RXP-C | GIAAREPNSHDGGGSAHARVPFFSHSRDLWRKPAKSL |
RXP-D | WEEPRRPFTMSGGGSAETHARVPFYSHSPMRHRLPGVHL |
RXP-E | SDDLRSPQLHNGGGSAVPFYSHSHMVRRKPRNPR |
The class that Cx43SP3, which is Mario Delmar et al. 2006, to be screened by display technique of bacteriophage can be with
Cx43 carboxyl terminal(Amino acid 255-382)The polypeptide of specific binding, by 34 Amino acid profiles.It is basic to be with reference to block
RXP-X, therefore be called and do the serial polypeptides of RXP, it is envisaged for antiarrhythmic therapy.Wherein RXP-E has more compared with other polypeptides should
Use prospect.
Embodiment 2:Prepare Cx43 targeting molecule probes
The general structure of Cx43 targeting molecules probe of the present invention is as shown in Figure 1.
(1)Imaging target spot is inserted by connexin 43 (Connexin 43, Cx43), and Cx43 carboxyl terminal (C-terminal) has
One gate nutty structure, function equivalent to specific receptor domain, be Cx43SP mainly in combination with target spot, be this hair
The target spot of bright Cx43 targeted imagings.
(2)Signal component:It is the part that probe is available for iconography equipment to detect, predominantly radio isotope in this patent
(PET and SPECT imagings), fluorescent dye and quantum dot(Optical imagery), paramagnetic material and superparamagnetic material and magnetic receives
Rice corpuscles(Magnetic resonance imaging), ultrasonic microbubble(Ultrasonic imaging), various optoacoustic nano particles(Photoacoustic imaging)And any of the above group
Divide the iconography material for the multi-modal imaging technology for detection being combined.
(3)Target affine component:It is probe and the part of the molecular target specific binding of imaging, combination therebetween
With high degree of specificity and high-affinity, equivalent to the relation of " key and lock ".It is mainly concerned with the present invention in embodiment 1
Polypeptide and small molecule structure.
(4)Connector:The part that signal component and the affine component of targeting are connected.Also connector can not be introduced, and
It is directly to be directly connected to signal component and the affine components of Cx43 using chemical method.
Embodiment 3:The preparation of the Cx43 targeted molecular probes of labelled with radioisotope
4 class polypeptides can be specifically bound with Cx43 carboxyl terminal in embodiment 1, therefore be can use and be prepared into mark
Cx43 targeted molecular probes.In following building-up process citing, representative polypeptide is used as with Cx43SP1.
Signal group is divided into positron emitting radio isotope or Single Photon Emission nucleic, available for clinical and small
Animal positron emission tomography (PET) or single photon emission computerized tomgraphy(SPECT).The appropriate connector of selection, passes through
Radio chemistry method can link together radio isotope and targeted polypeptide.The connector of use, which is called, does difunctional
Chelating agent.Bifunctional chelating agent both had the function block group combined with radioactive metal, also there is the base combined with Cx43SP
Group, the two is connected, as Cx43 targeting molecule probes.
1)Divalence(M2+)Or trivalent metal ion(M3+)Mark Cx43SP
It can select different connectors according to radionuclide different qualities, refer to table 2.
Thus table 2 often synthesizes with radio isotope, bifunctional chelating agent and Cx43 targeting probes
Note:R is Cx43SP.
DTPA:Diethylene triamine pentaacetic acid diethylenetriamine pentaacetic acids
DOTA:1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 1,4,7,
10- tetraazacyclododecanand -1,4,7,10- tetraacethyls
DOTAGA:
1-(1-carboxy-3-carboxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7,
10-triacetic acid
1- (1- carboxyl -3- carboxylics propyl group)-Cyclen -1,4,7,10- tetraacethyls
NOTA:1,4,7-triazacyclononane-1,4,7-triacetic acid 1,4,7- sodium azide -1,4,
7- triacetic acids
NODAGA:NOTA carries out functionalized modification by glutaric acid arm
2-(p-SCN-Bz)-NOTA:NOTA carries out functionalized modification by benzyl isothiocyanic acid
TETA:1,4,8,11-tetraazacyclotetradecane-1,4,8,11,tetraacetic acid1,4,
8,11- macrocyclic tetraamines tetraacethyl -1,4,7,10- tetraacethyls
CB-TE2A:Attachment of two carboxymethyl pendant arms to cross-bridged
(CB)-cyclam leads to CB-TE2A
Sar:sarcophagine(3,6,10,13,16,19-hexa azabicyclo[6.6.6]icosane)
Cobalt ions(3,6,10,13,16,19- hexabromos azabicyclo [6.6.6] icosane)
SarAr and AmBa Sar are Sar carboxylic acids and aminoderivative
NODA:1,4,7-triazacyclononane-1,4-diacetate 1,4,7- sodium azide -1,4- diacetic acids
Sodium
Due to a variety of radio isotopes and bifunctional chelating agent referred to above, herein with64Exemplified by Cu marks Cx43SP,
Illustrate radioisotopic divalence(M2+)Or trivalent metal ion(M3+)The method for marking Cx43SP.
NODA modifies Cx43SP:NODA is excessive, plus appropriate DMF (DMF) and 2% N, N- diisopropyl
Base ethylamine (DIPEA), room temperature concussion is stayed overnight.High performance liquid chromatography (HPLC) is isolated and purified, mass spectral analysis identification product.NODA
The chemical equation for modifying Cx43SP1 is as follows:
NODA modifies Cx43SP1 chemical equation
64Cu is marked:Its 10 μ g Cx43SP-NODA is dissolved in the μ l buffer solutions of ammonium acetate 200 of the pH between 4-5,
Add 50 μ L's64CuCl2(PH is between 5-6).Mixed liquor reacts 1 hour in 37 °C.Radiolabeled product is through putting
Penetrating property detector-high performance liquid chromatography (RP-HPLC) is isolated and purified, and determines mark rate, radiochemically pure, specific activity.64Cu is marked
NODA-Cx43SP1 chemical equation is as follows:
64Cu marks NODA-Cx43SP1 chemical equation
2)18F marks Cx43SP
18F is clinical the most frequently used radionuclide, using compatibility18F-F-Direct labeling polypeptide difficulty is very big, typically
Using by modification18F precursors, such as 4- nitrobenzene 2- [18F] fluorine propionic acid(18F-NFP).By this technology, it can obtain being adapted to use
It is imaged in heart and tumour Cx43 targeted moleculars18The characteristics of Cx43 probes of F marks, probe is latent with more clinical practice
Power.
18F-FP-Cx43SP synthesis:
18The precursor of F marks18F-NFP (4-nitrophenyl 2- [18F]-fluoropropionate, Rt=22-
23min), the Cx43 targetings μ g of binding peptide 500 are dissolved in 150 μ L anhydrous dimethyl sulphoxides(DMSO)In, and add18F-NFP and 20 μ L
DIPEA(DIPEA).Mixed liquor reacts the 5% acetic acid neutralization that 800 μ L are added after 30 minutes at room temperature.Product
Purified through semi-preparative HPLC C-18 posts.Purified product adds the dilution of 20 μ L water.5mL ethanol and 10mL water are used in preparation process
C-18 pillar eluted products are rinsed repeatedly, and final product is dried up at 60 °C with nitrogen.Finally,18The polypeptide of F marks is dissolved in PBS
And by 0.22 μm of hyperfiltration into disinfectant measuring bottle, for external and experiment made on the living.Equally, mark rate is determined with HPLC,
Radiochemically pure, specific activity etc..18F marks Cx43SP1 chemical equation is as follows:
18F marks Cx43SP1 chemical equation
18F-AlF-NODA-Cx43SP synthesis:
With NODA-Cx43SP, NODA-Cx43SP is synthesized.Using QMA-SepPak posts absorption 30mCi (1.1GBq)18F- fluorine
Change aluminium, rinsed with the 2.5mL non-metallic ion aqueous solution18F- aluminum fluorides, and eluted with 400 μ L 0.4M KHCO3 solution18F-
Aluminum fluoride, takes 200 μ L's18F- aluminun fluoride solutions are standby.Solution ph is adjusted to 4.0 with the acetic acid of not metal ion.Xiang Rong
Aluminium chloride is sequentially added into liquid(AlCl3, 2mM, 3 μ L are dissolved in 0.1M sodium-acetate buffers, pH4) and 5 μ L NOTA-
Cx43SP(60mg/mL is dissolved in DMSO).After 100 °C of reactant mixture is incubated 15 minutes, diluted with 1mL non-metallic ions water, production
Thing prepares HPLC purifying through half, collects18F-AlF-NOTA-Cx43SP analogs, are evaporated, and are dissolved in PBS and super by 0.22 μm
Microfiltration is into disinfectant measuring bottle, for external and experiment made on the living.Equally, mark rate, radiochemically pure, than work are determined with HPLC
Degree etc.,18F marks Cx43SP1 chemical equation is as follows.
18F marks Cx43SP1 chemical equation
Except18, can also be by other outside F-NFP18F precursors(It is exactly auxiliary group), marked using similar method
Cx43SP.Conventional18F labelled precursors structural formula [18F]FBA:[18F] o-fluorobenzoic acid;[18F]FSB:[18F] fluorobenzoate;
[18F]FBEM[18F] FBBO is as follows:
Except18Outside F, it can also apply11C、13N、15The radionuclides such as O, choose corresponding precursor, and Cx43SP is carried out
Mark.The advantage of the probe of the radioisotope labeling of positron emission:Sensitiveness is high, can accurate quantitative analysis, can clinic convert, spy
Pin molecular weight is small, and pharmacokinetic profile is good.
3):99mTc marks Cx43SP
Citing:99mTcO3+Or99mTcO2+, bifunctional chelating agent is used as using HYNIC.Comprise the following steps that:
1. the amino on bifunctional chelating agent HYNIC-NHS and Cx43SP(-NH2)Reaction, using DMF as solvent, 2%DIPEA
As catalyst, through high pressure liquid phase (HPLC) after purification, product, mass spectrum is confirmed.
2. technetium-99 m labeled HYNIC-Cx43SP:By the scheme of the two end number mixing ligand complex of " 3+1 ", with tridentate ligand
Tricine makees collaboration reagent, with stannous chloride (SnCl2·H2O)Make after reducing agent, room temperature reaction 20min, determine mark chemical combination
The radiochemical purity of thing, the colloid of casting is less than 1%.
3. analysis:With the method for thin-layer chromatography (ITLC) and high pressure liquid phase (HPLC) come colloid in evaluation of markers compound
The content of content and product.
99mTc marks Cx43SP1 chemical equation is as follows:
99mTc marks Cx43SP1 chemical equation
According to different99mTc- cores, select different connectors, by different courses of reaction, can obtain different structure
Product.99mTc marks Cx43SP, common bifunctional chelating agent and the probe of synthesis, and it is as shown in table 2 that R represents Cx43SP:
Table 2
4)123/124I marks Cx43SP
The appropriate oxidant of selection, connecing can be marked at iodine radioisotope on Cx43SP.Mainly there are 2 kinds of mark sides
Method, directly mark and indirect labelling.
1. directly mark:Iodination reaction can be realized directly by " iodine protonation ".123/124I directly marks Cx43SP normal
The oxidant structural formula of use is as follows:
123/124I directly marks Cx43SP1 chemical equation as follows:
2. indirect labelling:123/124I indirect labellings Cx43SP frequently with oxidant structural formula it is as follows:
123/124I indirect labellings Cx43SP1 chemical equation is as follows:
Embodiment 4:The preparation of the Cx43 targeted molecular probes of optical markings
1)Near infrared fluorescent dye marks Cx43SP1
Wavelength 700-900nm near infrared fluorescent dye due to penetration power it is stronger, reach deeper part tissue, therefore
It is commonly used to carry out chemiluminescence assay.Conventional near infrared fluorescent dye is shown in figure.Different bifunctional chelating agents may be selected, nearly
IR fluorescent dyes are marked on Cx43SP.Cyanine dye chemical structure of general formula is as follows:
The chemical constitution of conventional 4 class near infrared fluorescent dyes is as follows:
(1a) cyanine, (1b) ICG, (1c) SIDAG, (1d) PPCy
Cyanine dye chemical structure of general formula
Cy5.5 is marked:Cx43 specific binding peptides are dissolved in 100 μ L DMSO, with Cy5.5-NHS under the conditions of lucifuge(1
equiv.)Mixing, is codissolved in 2% DIPEA, room temperature, and vibrations are incubated overnight.Product prepares HPLC C18 pillars (250 through half
× 10mm) isolate and purify, product is collected, is freezed, yield is calculated, uses mass spectrum(MALDI-TOF-MS)Determine molecular weight.Cy5.5 is marked
Remember that Cx43SP1 chemical equation is as follows:
2), near-infrared nano material mark Cx43SP
The most frequently used at present have a following four classes nano material, including:Include nano-probe, the amount of near infrared fluorescent dye
Sub- point, CNT, gold nanoclusters.
By taking near-infrared quantum dots as an example, using quantum dot-labeled Cx43SP:Cx43SP1000eq is taken, it is soluble in water, with 1eq
Quantum dot mixing, add 1000eq EDC, be stirred at room temperature reaction 1 hour, with PD10 pillars separate, concentrated with centrifuge tube, survey
Concentration.500-600 Cx43SP molecule can be marked on one quantum dot.The probe of synthesis is lived through near-infrared fluorescence imaging
Physical examination is surveyed.
Embodiment 5:The preparation of the Cx43 targeted molecular probes of magnetic mark
1)Superparamagnetic nanoparticle(Fe3O4)
Cx43SP synthesising probing needles are marked using superparamagnetic nanoparticle, for magnetic resonance imaging.With super-paramagnetism nano
Exemplified by particle, Cx43SP is marked using superparamagnetic nanoparticle:Cx43SP 1000eq are taken, it is soluble in water, it is super suitable with 1eq
Magnetic nano-particle is mixed, and adds 1000eq EDC, and reaction 1 hour is stirred at room temperature, and is separated with PD10 pillars, dense with centrifuge tube
Contracting, surveys concentration.Marked by superparamagnetism iron oxide Cx43SP1 chemical equation is as follows:
2)Paramagnetic metal chelates:, can also be by paramagnetic metal chelates by selecting appropriate bifunctional chelating agent
It is marked on Cx43SP, probe is formed, for magnetic resonance imaging.Paramagnetic metal element mainly includes:Gadolinium(Gd3+)、Dy3+、Tm3 +、Mn2+, CEST reagents3He,129Xe.Due to paramagnetic metal chelates produce relaxation ability it is weaker, and magnetic resonance molecule into
The sensitiveness of picture is relatively low, can also introduce effective signal amplification mechanism, that is, utilizes the macromoleculars, surface such as numerous body, liposome
Multiple functional groups are carried, multiple Cx43SP molecules and substantial amounts of paramagnetic metal are chelated into its surface, a probe is formed.It is suitable
Magnetic metal chelate labels Cx43SP1 chemical equation is as follows:
Embodiment 6:The preparation of the Cx43 targeted molecular probes of ultrasonic microbubble mark
Cx43SP 1000eq are taken, it is soluble in water, mixed with 1eq ultrasonic microbubble, add 1000eq EDC, be stirred at room temperature
Reaction 1 hour.Ultrasonic microbubble mark Cx43SP1 chemical equation is as follows:
Embodiment 7:The preparation of the Cx43 targeted molecular probes of photoacoustic material mark
At present, there are some golden nanometer particles also to can be used to mark Cx43SP, carry out photoacoustic imaging, such as gold nanorods.Should
Cx43SP is marked with gold nanorods:Cx43SP 1000eq are taken, it is soluble in water, mixed with 1eq gold nanorods, add 1000eq
EDC, be stirred at room temperature reaction 1 hour, with PD10 pillars separate, concentrated with centrifuge tube, survey concentration.Gold nanorods are marked
Cx43SP1 chemical equation is as follows:
Embodiment 8:The preparation of the Cx43 targeted molecular probes of multi-mode mark
2 kinds above or a variety of iconography labeling methods are used simultaneously, generation is available for 2 kinds or the inspection of two or more iconography
Look into the Cx43 targeting probes of means detection, i.e. multi-mode molecular imaging probe.For example connected in nano-material surface different
Functional group, the developer for other patterns such as connecting peptides, radionuclide, fluorescent dyes.
On near-infrared quantum dots surface through sulfydryl and carboxyl modified, upper Cx43SP1 is first connected, quantum is modified with NODA-MAL
Point, by the sweet reaction with sulfydryl in Malaysia, by NODA connections over the qds.Use again64Cu is marked, radiolabeled product warp
PD10 is isolated and purified, and determines mark rate, and radiochemically pure, specific activity, probe is available for near-infrared fluorescence imaging and PET to be imaged simultaneously
Detection.64Cu and the double mode mark Cx43SP1 of quantum dot chemical equation are as follows:
Embodiment 9:Isolated experiment is proved
1), Cx43 high-expression cell lines foundation:Cervical Cancer HeLa Cells have been transfected with Cx43 genes, Cx43 is successfully prepared
Cervical Tumor cell line HeLa-Cx43 is overexpressed, by for the Hela cells of transgenosis(Without C43 expression)It is used as control.
2)Cy5.5-Cx43SP1 cells are combined and blocking experiment:Hela-Cx43 cells and control group Hela-Control are thin
Born of the same parents, 0.5X106/ hole, experiment the previous day is laid on 12 orifice plates, totally four groups:A groups:Hela-Cx43 groups of cells, B groups:Hela-
Control groups of cells, C groups:Hela-Cx43 cells blocks groups, D groups:Hela-Control cells blocks groups.Every group of 3 holes, experiment
It is repeated 3 times.Cy5.5-Cx43SP1 is added per hole, concentration is 500nmol/L, 1ml.Blocking group adds the Cx43SP1 of no mark,
Concentration is 5 μm of ol/L.
As a result show:There is obvious specific binding in Cy5.5-Cx43SP1, with HeLa-Cx43 cells with untransfected
The control group HeLa cells of Cx43 genes are then without combination(Fig. 2-a, Fig. 2-b).Introduce excessive 5 μm of un-marked ol/L's
After Cx43SP is blocked, the combination of Cy5.5-Cx43SP and HeLa-Cx43 cells is significantly lowered significantly(Fig. 2-c).Result above
Show, near infrared fluorescent probe Cy5.5-Cx43SP can be over-expressed Cx43 HeLa cell-specifics intake, Cy5.5-
Cx43SP and HeLa-Cx43 combination has targeting specific.
Meanwhile, tissue freezing section has further been made, has been imaged under fluorescence microscope.Control is used as using muscle(Fig. 3-
a,3-b,3-c), fluorescence microscopy Microscopic observation probe Cy5.5-Cx43SP is in the distribution situation of heart, tail vein injection Cy5.5-
Shown under 1h after Cx43SP, myocardium frozen section fluorescence microscope, Cy5.5-Cx43SP largely assembles in cardiac muscular tissue, and mainly
It is distributed in position where the connection of gap between cardiac muscle cell(Fig. 4-a, 4-b, 4-c).Confirm probe to myocardium gap in tissue level
Connection has targeting specific.
3)、64Cu-NODA-Cx43SP1 cells are combined and blocking experiment
Hela-Cx43 cells and control group Hela-Control cells, 0.5X106/ hole, experiment the previous day is laid on 12 holes
Plate, totally four groups:A groups:Hela-Cx43 groups of cells, B groups:Hela-Control groups of cells, C groups:Hela-Cx43 cells blocks groups,
D groups:Hela-Control cells blocks groups.Every group of 3 holes, experiment is repeated 3 times.Added per hole64Cu-NODA-Cx43SP1, concentration
For 3.2 μ Ci/ holes, 1ml.Blocking group adds the NODA-Cx43SP1 of no mark, and concentration is 50 μ g/ holes(10 times64Cu-NODA-
Cx43SP1).As a result show:64There is obvious specific binding in Cu-NODA-Cx43SP1, with HeLa-Cx43 cells with not turning
The control group HeLa cells of Cx43 genes are contaminated then without combination.Blocking experiment,64Cu-NODA-Cx43SP1 and HeLa-Cx43 cells
With reference to significantly lowering significantly(Fig. 5).As a result show ,-NODA-Cx43SP1 can be over-expressed Cx43 HeLa cell-specifics
Intake ,-NODA-Cx43SP1 and HeLa-Cx43 combination has targeting specific and high-affinity.
Embodiment 10:, zoopery
1), probe living biological distribution characteristics:
Bio distributions of the Cy5.5-Cx43SP in normal mouse
Cy5.5-Cx43SP is injected after mono- hour, mouse is put to death, exteriorizes, in vitro major organs near-infrared fluorescent is carried out
Imaging display, as a result shows:Probe Cy5.5-Cx43SP is distributed mainly on heart, liver, and intestines and stomach are mainly arranged through liver sausage road
Let out, partly through kidney, urinary system excretion.Especially its higher heart intake, this is to express higher Cx43 with normal heart
It is very consistent(Fig. 6).
2), normal rat PET cardiac imagings:
Previous experiments are in live body level verification64Cu-NOTA-Cx43SP normal rat heart targeting ability of aggregation and
The biodistribution characteristic of probe.As a result show,64Cu-NOTA-Cx43SP 30min after intravenous injection go out in cardia
Now significantly build up, be continued until that 3h still has aggregation (Fig. 7), and it is seldom in the aggregation of liver, lungs, and myocardial visualization is clear.
Because Cx43 is myocardium major gap connection albumen, as a result illustrate64Cu-NOTA-Cx43SP assembles in homing ability to myocardium.Vein is noted
Penetrate after 1h, probe exists64Cu-NOTA-Cx43SP mouse are distributed mainly on heart, enteron aisle.These results and mouse Cy5.5-
The external optical imaging results of Cx43SP are consistent.The experimental result, indicates the Cx43 targeted molecular probes designed by preliminary experiment64Cu-NOTA-Cx43S can carry out living imaging to cardiac muscle.
3), normal mouse PET cardiac imagings:
Carry out simultaneously64Cu-NOTA-Cx43SP images experiment in the PET of normal mouse.As a result such as Fig. 8.64Cu-NOTA-
Cx43SP is now significantly built up after intravenous injection after 1 hour in cardia, while having absorption in liver, and much passes through kidney
And bladder drainage.These results have uniformity with rat test, but Heart Imaging result is poor compared with rat.Illustrate probe not
In same animal species, bio distribution has different.Meanwhile,64Cu-NOTA-Cx43SP probes also have what is further optimized
Space and demand.
4)Tumor bearing nude mice optical tumor is imaged:
Xenografts in nude mice model is established using the HeLa-Cx43 cells for being overexpressed Cx43(Fig. 9, left side), and with
Untransfected Cx43 conventional H eLa cell subcutaneous transplantation knurls model is as a control group(Fig. 9, right side).Carry out live body Cy5.5-
Cx43SP1 tumour near-infrared fluorescence imagings, as a result show:Probe Cy5.5-Cx43SP1 is after tail vein injection one hour, in mistake
The HeLa-Cx43 tumor locus for expressing Cx43 is assembled in high concentration, and has no and significantly build up in control group HeLa tumor locus.Should
As a result show again:In live body level, Cx43 targeted molecular probe Cy5.5-Cx43S have certain to tumour positive Cx43
Targeting specific.
5), tumor bearing nude mice PET tumor imagings:
Xenografts in nude mice model is established using the HeLa-Cx43 cells for being overexpressed Cx43(Figure 10, left side).Vein
64Cu-NODA-Cx43SP is injected, concentration is 40 microcuries.Micro PET imaging results show:Probe 64Cu-NODA-Cx43SP
After tail vein injection one hour, assemble in the HeLa-Cx43 tumor locus for being overexpressed Cx43 in high concentration.The result shows again
Show:In live body level, tumour positive to Cx43 Cx43 targeted molecular probe 64Cu-NODA-Cx43SP has certain target
To specificity.
Described above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, under the premise without departing from the principles of the invention, some improvements and modifications can also be made, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (6)
1. a kind of method of living body molecule imaging, methods described includes:
Cx43 targeting molecule probes are provided, the Cx43 targeting molecules probe targets affine component by signal component, Cx43
And the part of connector three is constituted, the signal group is divided into the part for being available for iconography equipment to detect, the Cx43 targetings are affine
Component is the polypeptide portion specifically bound with Cx43, and the connector connects signal component and the affine component of targeting;
With described Cx43 targeting molecules probe to patient position to be measured implement optical imagery, positron emission fault into
Picture, single photon emission tomographic imaging, magnetic resonance imaging, photoacoustic imaging, ultrasonic imaging or other live body iconography fusion of imaging skills
Art preferred PET/CT or PET/MRI;
The Cx43 targets affine component and Cx43 carboxyl terminal is specifically bound;
The affine component of targeting of the Cx43 is selected from:
Ith, Cx43SP1, Gly-Ala-Pro-Gly-4Hyp-Pro-Tyr
IIth, Cx43SP2, Gly-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly
IIIth, Cx43SP3, its structural formula is as follows:
The connector is selected from DTPA, DOTA, DOTAGA, NOTA, NODAGA, TETA, CB-TE2A, Sar or NODA, or utilizes
Other directly chemically react and are directly connected to signal component and the affine components of Cx43;
The signal group of the Cx43 targetings probe is selected from radio isotope, fluorescent dye.
2.Cx43 targeting molecule probe, affine component is targetted and signal component and targeting is close by signal component, Cx43
The part of connector three composition connected with component, the signal group is divided into the part for being available for iconography equipment to detect, described
It is the part specifically bound with Cx43 to target affine component, and the connector connects signal component and the affine component of targeting
Come;
The affine component of targeting and Cx43 carboxyl terminal are specifically bound;
The affine component of targeting is selected from:
Ith, Cx43SP1, Gly-Ala-Pro-Gly-4Hyp-Pro-Tyr
IIth, Cx43SP2, Gly-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly
IIIth, Cx43SP3, its structural formula is as follows:
The signal group is selected from radio isotope, fluorescent dye;
The connector is selected from DTPA, DOTA, DOTAGA, NOTA, NODAGA, TETA, CB-TE2A, Sar or NODA, or utilizes
Other directly chemically react and are directly connected to signal component and the affine components of Cx43.
3. a kind of composition of molecular imaging probe, includes the targeting molecule probe described in claim 2.
4. use of the targeting molecule probe described in claim 2 in the reagent for preparing diagnosis Cx43 abnormal expression relevant diseases
On the way.
5. purposes according to claim 4, it is characterised in that the Cx43 abnormal expressions relevant disease is all adjoint
Cx43 expresses the congenital or acquired disease day after tomorrow with dysfunction.
6. purposes according to claim 5, it is characterised in that the Cx43 abnormal expressions relevant disease is tumour or painstaking effort
Guard system disease is preferably arrhythmia cordis.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210200690.6A CN102743770B (en) | 2012-06-18 | 2012-06-18 | A kind of targeting molecule image probe and living body molecule imaging method |
US14/353,111 US9764048B2 (en) | 2012-06-18 | 2012-07-30 | Targeted molecular imaging probe and method for in vivo molecular imaging |
PCT/CN2012/079344 WO2013189113A1 (en) | 2012-06-18 | 2012-07-30 | Targeted molecular imaging probe and method for in vivo molecular imaging |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210200690.6A CN102743770B (en) | 2012-06-18 | 2012-06-18 | A kind of targeting molecule image probe and living body molecule imaging method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102743770A CN102743770A (en) | 2012-10-24 |
CN102743770B true CN102743770B (en) | 2017-07-21 |
Family
ID=47024490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210200690.6A Expired - Fee Related CN102743770B (en) | 2012-06-18 | 2012-06-18 | A kind of targeting molecule image probe and living body molecule imaging method |
Country Status (3)
Country | Link |
---|---|
US (1) | US9764048B2 (en) |
CN (1) | CN102743770B (en) |
WO (1) | WO2013189113A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103333079B (en) * | 2013-07-03 | 2016-08-17 | 广东回旋医药科技股份有限公司 | Imino group acids PET developer and preparation method and application |
WO2015051362A1 (en) * | 2013-10-04 | 2015-04-09 | Illinois Institute Of Technology | Multifunctional chelators, complexes, and compositions thereof, and methods of using same |
CN104483296B (en) * | 2014-12-01 | 2018-07-13 | 无锡市人民医院 | Breast cancer molecular probe and its manufacturing method |
FR3043398B1 (en) * | 2015-11-09 | 2017-12-29 | Arc Int France | METHOD FOR MANUFACTURING A HOLLOW GLASS ARTICLE |
CN107137060B (en) * | 2017-04-14 | 2019-11-05 | 同济大学 | A kind of gold nanosphere being easily metabolized/chicken egg white composite Nano optoacoustic probe and its preparation |
US10093741B1 (en) | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
JP2020518673A (en) | 2017-05-05 | 2020-06-25 | フュージョン・ファーマシューティカルズ・インコーポレイテッド | Enhanced pharmacokinetics of bifunctional chelates and their use |
KR20200004861A (en) | 2017-05-05 | 2020-01-14 | 퓨전 파마슈티칼즈 인크. | IGF-1R monoclonal antibodies and uses thereof |
CN107669659B (en) * | 2017-09-20 | 2020-12-29 | 华中科技大学同济医学院附属协和医院 | Preparation method of folate receptor targeted substrate-loaded nano microbubble |
CN107647852B (en) * | 2017-11-16 | 2020-05-12 | 重庆医科大学 | System and method for imaging in organism tissue |
CN108451507A (en) * | 2018-04-28 | 2018-08-28 | 国家纳米科学中心 | Probe in detecting changing device and toy optoacoustic tomographic system |
AU2021295552A1 (en) * | 2020-06-23 | 2022-11-03 | Bracco Imaging Spa | Near-infrared cyanine dyes and conjugates thereof |
CN112876538B (en) * | 2021-02-04 | 2022-09-30 | 福建医科大学 | Polypeptide targeting neovascular marker CD105 and application thereof |
CN113943243B (en) * | 2021-10-14 | 2023-08-01 | 南开大学 | Preparation and application of fluorine probe for simultaneously identifying and quantifying amino acid |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10925977B2 (en) * | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
US20100298225A1 (en) * | 2007-07-15 | 2010-11-25 | Bjarne Due Larsen | Peptide gap junction modulators |
-
2012
- 2012-06-18 CN CN201210200690.6A patent/CN102743770B/en not_active Expired - Fee Related
- 2012-07-30 WO PCT/CN2012/079344 patent/WO2013189113A1/en active Application Filing
- 2012-07-30 US US14/353,111 patent/US9764048B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN102743770A (en) | 2012-10-24 |
US9764048B2 (en) | 2017-09-19 |
US20150202335A1 (en) | 2015-07-23 |
WO2013189113A1 (en) | 2013-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102743770B (en) | A kind of targeting molecule image probe and living body molecule imaging method | |
Wu et al. | Multimodal molecular imaging: current status and future directions | |
Wang et al. | Activatable multimodal probes for in vivo imaging and theranostics | |
Dobrucki | Imaging angiogenesis | |
Weissleder | Molecular imaging: exploring the next frontier | |
Ogawa et al. | Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection | |
Zhou et al. | Tumor-homing peptide-based NIR-II probes for targeted spontaneous breast tumor imaging | |
US20080118439A1 (en) | Systems and methods for high-resolution in vivo imaging of biochemical activity in a living organism | |
WO2013185487A1 (en) | Tumor-targeting multi-mode imaging method for living body based on gold nanoclusters | |
CN107652358A (en) | A kind of uPAR targeted polypeptides, probe and living body molecule developing method | |
Hai et al. | Intracellular self‐assembly of nanoprobes for molecular imaging | |
Ding et al. | UPAR targeted molecular imaging of cancers with small molecule-based probes | |
US9642922B2 (en) | Caspase-triggered nano-aggregation probes and methods of use | |
CN105126128A (en) | Novel tumor VEGFR-3 molecular photographic developer and application thereof | |
TWI765195B (en) | Dual-targeted carbonic anhydrase ix complex and a contrast agent thereof | |
Wang et al. | Firefly Luciferin‐Inspired Biocompatible Chemistry for Protein Labeling and In Vivo Imaging | |
Yu et al. | An NIR Fluorescence Turn‐on and MRl Bimodal Probe for Concurrent Real‐time in vivo Sensing and Labeling of β‐Galactosidase | |
CN112961215B (en) | Polypeptide and tumor targeting peptide, tumor detection reagent, tumor surgery navigation contrast medium and tumor targeting drug thereof | |
CN110357945A (en) | A kind of Coxsackie virus/adenovirus the simulating peptide and its application of target tumor | |
CN113274511B (en) | Diagnostic imaging agent for nerve injury and preparation method thereof | |
US9044505B2 (en) | Multimeric biotinidase resistant multimodality probes | |
Genady et al. | A bioorthogonal methylene blue derived probe for targeted photoacoustic imaging | |
Qu et al. | A novel magnetic resonance contrast agent for detection of hepatic segmental function | |
CN115607695B (en) | Preparation method and application of bevacizumab multi-mode molecular probe | |
Malone et al. | Molecular imaging: The Convergence of form and function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170721 Termination date: 20190618 |
|
CF01 | Termination of patent right due to non-payment of annual fee |